Food Frequency Questionnaire to Assess Sodium Intake (EVALSEL)
Primary Purpose
Hypertension, Renal Insufficiency
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Questionnaire
Sponsored by
About this trial
This is an interventional diagnostic trial for Hypertension focused on measuring natriuresis, Hypertension, Renal insufficiency, Sodium, Table salt
Eligibility Criteria
Inclusion Criteria:
- Patients with high blood pressure, CKD stages 4-5 and patients free from any diseases
- Patients over 18 years old
- Patients in nephrology and cardiology consultation or recruited by CIC
- Patients with health insurance
- Patients willing to follow the full study
Exclusion Criteria:
- Loss of salt by vomiting, diarrhea or sweating (intense sport or intense fever 3 days before urine collection) which can cause a decreasing natriuresis
- Modification of the therapeutic management of patients during the study period
- Taking certain drugs like effervescent drugs, Gaviscon and Tolvaptan during the day of urine collection, as well as diuretics (unless they are taken long-term and the diuresis is stable) which can cause an increasing natriuresis
- Pregnant or breastfeeding women
- Patients protected by law
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Experimental group
Arm Description
patients with high blood pressure or chronic kidney diseases stages 4-5
Outcomes
Primary Outcome Measures
Intra-class correlation coefficient between the quantitative measurement of sodium consumption and the 24-hour natriuresis measurement and verification of the 24-hour creatininuria values
Intra-class correlation coefficient between the quantitative measurement of sodium consumption by the EvalSel questionnaire and the 24-hour natriuresis measurement (amount of sodium in 24-hour urine) and verification of the 24-hour creatininuria values (amount of creatinine in 24-hour urine) to confirm that the urine collection was performed correctly.
Secondary Outcome Measures
Full Information
NCT ID
NCT05533645
First Posted
September 5, 2022
Last Updated
September 5, 2022
Sponsor
University Hospital, Lille
1. Study Identification
Unique Protocol Identification Number
NCT05533645
Brief Title
Food Frequency Questionnaire to Assess Sodium Intake
Acronym
EVALSEL
Official Title
Development and Validation of a Food Frequency Questionnaire to Assess Sodium Intake in Hospitalized Patients or in Medical Consultation
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
February 2023 (Anticipated)
Primary Completion Date
August 2024 (Anticipated)
Study Completion Date
August 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Lille
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
EvalSel can precisely assess the salt intake of hospitalized patients in nephrology and cardiology or in medical consultation. It can determine salt consumption to the nearest gram.
The objectives of this food frequency questionnaire are to arrive at a precise dietary diagnosis and to quickly identify the dietary errors made by the patients.
EvalSel is useful for doctors to quickly obtain an assessment of the salt consumption of their patients, so they can refer them to dietitians if necessary. It can be used on the day of admission to hospital or during medical follow-ups to know the evolution of their consumption over the long term and improve their care.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Renal Insufficiency
Keywords
natriuresis, Hypertension, Renal insufficiency, Sodium, Table salt
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
99 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Experimental group
Arm Type
Experimental
Arm Description
patients with high blood pressure or chronic kidney diseases stages 4-5
Intervention Type
Other
Intervention Name(s)
Questionnaire
Intervention Description
These patients complete the food frequency questionnaire in order to validate it for lower sodium consumptions. The experimental group has already received dietary advices regarding salt consumption during during their recent consultations.
Primary Outcome Measure Information:
Title
Intra-class correlation coefficient between the quantitative measurement of sodium consumption and the 24-hour natriuresis measurement and verification of the 24-hour creatininuria values
Description
Intra-class correlation coefficient between the quantitative measurement of sodium consumption by the EvalSel questionnaire and the 24-hour natriuresis measurement (amount of sodium in 24-hour urine) and verification of the 24-hour creatininuria values (amount of creatinine in 24-hour urine) to confirm that the urine collection was performed correctly.
Time Frame
through study completion an average of 18 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with high blood pressure, CKD stages 4-5 and patients free from any diseases
Patients over 18 years old
Patients in nephrology and cardiology consultation or recruited by CIC
Patients with health insurance
Patients willing to follow the full study
Exclusion Criteria:
Loss of salt by vomiting, diarrhea or sweating (intense sport or intense fever 3 days before urine collection) which can cause a decreasing natriuresis
Modification of the therapeutic management of patients during the study period
Taking certain drugs like effervescent drugs, Gaviscon and Tolvaptan during the day of urine collection, as well as diuretics (unless they are taken long-term and the diuresis is stable) which can cause an increasing natriuresis
Pregnant or breastfeeding women
Patients protected by law
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
David GUYONNET
Phone
0320445962
Email
david.guyonnet@chru-lille.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
d GUYONNET
Organizational Affiliation
University Hospital, Lille
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Food Frequency Questionnaire to Assess Sodium Intake
We'll reach out to this number within 24 hrs